Humana (NYSE:HUM) Issues Quarterly Earnings Results

Humana (NYSE:HUM) posted its quarterly earnings results on Tuesday. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10, Zacks reports. Humana had a net margin of 1.18% and a return on equity of 13.20%. Humana updated its FY 2025 guidance to 16.250-16.250 EPS.

Humana Stock Down 2.7 %

Shares of NYSE HUM opened at $266.91 on Tuesday. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $32.14 billion, a PE ratio of 23.64, a P/E/G ratio of 2.11 and a beta of 0.56. The firm has a fifty day moving average of $274.21 and a 200-day moving average of $297.52. Humana has a 52-week low of $213.31 and a 52-week high of $406.46.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on HUM. Bank of America raised Humana from an “underperform” rating to a “neutral” rating and lifted their price objective for the stock from $247.00 to $308.00 in a report on Wednesday, November 6th. Piper Sandler lifted their price target on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 15th. TD Cowen increased their price objective on shares of Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Morgan Stanley raised their target price on shares of Humana from $288.00 to $301.00 and gave the company an “equal weight” rating in a report on Tuesday, December 17th. Finally, Barclays upped their price target on shares of Humana from $253.00 to $255.00 and gave the company an “equal weight” rating in a report on Wednesday, January 22nd. Nineteen investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $297.68.

Insider Activity at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.32% of the stock is owned by insiders.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.